Social Media Sidebar

Announcement

Please sign up, comment on articles and bring your friends!

Current poll

PlanetTech is asking:

What do you think about our new web site?

Love it, indeed
Really good solution
Same as old one
The old one was better
This is a new option

Quote of the day

When seen through the lens of technology, few resources are truly scarce; they’re mainly inaccessible. 

 

Peter Diamandis

A new drug treatment cuts migraine days in half

RATE THIS! +38
Posted in Medicine on 7th Dec, 2017 10:15 PM by Alex Muller

Across the UK, an estimated 8.5 million people live with migraine and research suggests the condition is likely to impact the lives of almost 200,000 people every day. There is an urgent need for new treatment options and erenumab is the first and only fully human monoclonal antibody of its kind designed to specifically prevent migraine.

 

It works by blocking the calcitonin gene-related peptide (CGRP) receptor, which plays a critical role in migraine activation.

 
Amgen and Novartis, the codevelopers of erenumab, funded this Phase III STRIVE study.
 
‘STRIVE is the first fully reported Phase III study of the CGRP pathway monoclonal antibodies, and it clearly shows that blocking this pathway can reduce the impact of migraine,’ said Peter Goadsby, Director, NIHR-Wellcome Trust King’s Clinical Research Facility and Professor of Neurology at King’s College London.
 
‘The results of STRIVE represent a real transition for migraine patients from poorly understood, repurposed treatments, to a specific migraine-designed therapy. STRIVE, as with the monoclonal antibody developments generally, represents an incredibly important step forward for migraine understanding and migraine treatment.’
 
These data show erenumab can significantly reduce the number of monthly migraine days experienced by patients, with a 3.7-day and 3.2-day reduction with erenumab 140 mg and 70 mg, respectively, from a baseline of 8.3-days (1.8-day reduction with placebo).
 
Additionally, 50 per cent of patients treated with erenumab 140 mg had the number of days with migraine symptoms cut by at least half (this figure was 43.3 per cent following treatment with erenumab 70 mg, and 26.6 per cent with placebo). Results from the Migraine Physical Function Impact Diary (MPFID) show patients treated with erenumab also reported improved physical health and ability to participate in daily activities over the six month trial period. Erenumab has also been shown to be effective and tolerable over the long term with a safety profile comparable to placebo.
 
‘Migraine is too often trivialized as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives’ said Simon Evans, Chief Executive, Migraine Action. ‘The effects can last for hours – even days in many cases. An option that can prevent migraine and that is well tolerated is therefore sorely needed and we hope that this marks the start of real change in how this condition is treated and perceived.’
 
New England Journal of Medicine – Controlled Trial of Erenumab for Episodic Migraine
 
BACKGROUND
 
They tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene–related peptide receptor, for the prevention of episodic migraine.
 
METHODS
 
They randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months. The primary end point was the change from baseline to months 4 through 6 in the mean number of migraine days per month. Secondary end points were a 50% or greater reduction in mean migraine days per month, change in the number of days of use of acute migraine–specific medication, and change in scores on the physical-impairment and everyday-activities domains of the Migraine Physical Function Impact Diary (scale transformed to 0 to 100, with higher scores representing greater migraine burden on functioning).
 
CONCLUSIONS
 
Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine–specific medication over a period of 6 months

Tags: brainneuroscienceresearchbiologyanatomy

Read original article » Back to category

Comments



 

Recent headlines

  • Posted in Online on 2017-12-15 13:43:41
    The FCC votes to repeal the 2015 net neutrality rules..read more
    Posted in Science on 2017-12-15 13:34:37
    How Clinical Trials Are Making the Case for MDMA in.....read more
    Posted in Business on 2017-12-15 13:23:01
    Elon Musk: We Should Already Have a Lunar Base by Now..read more
    Posted in Business on 2017-12-14 01:48:06
    World Bank to stop financing oil, gas projects from 2019..read more
    Posted in Medicine on 2017-12-13 21:23:13
    Marijuana May Help HIV Patients Keep Mental Stamina Longer..read more
Posted in Business on 2013-10-10 01:33
China is working towards a manned lunar mission in about.....read more
Posted in Business on 2013-10-20 07:17
Spacex says China is their main competitor for commercial.....read more
Posted in Software on 2013-10-20 06:43
Pirate Bay Browser Clocks 1,000,000 Downloads..read more
Posted in Medicine on 2013-10-10 02:10
Google reportedly investing hundreds of millions into new.....read more
Posted in Medicine on 2013-10-14 03:13
Endothelial Cells Can Repair and Regenerate Organs,.....read more
Posted in Science on 01.01.2010
Spacex says China is their main competitor for commercial.....read more
Posted in Science on 01.01.2010
Staring at Your Phone Could Be Making You Short Sighted..read more
Posted in Science on 01.01.2010
Oculus Rift virtual reality headset coming to mobile, but.....read more
Posted in Science on 01.01.2010
China is working towards a manned lunar mission in about.....read more
Posted in Science on 01.01.2010
Delivering drugs via nanoparticles to target mitochondria..read more

Recent Blog Posts

  • Posted by AlexMuller
    Martian landscapes formed from sand 'levitating' on a little.....read more
    Posted by AlexMuller
    Scientists detect comets outside our solar system..read more
    Posted by AlexMuller
    Advanced artificial limbs mapped in the brain..read more
    Posted by AlexMuller
    Bacteria have a sense of touch..read more
    Posted by AlexMuller
    Recurrent brain cancer: New hope with phase 1 clinical trial.....read more

Login to your Account

Login to your PlanetTech Account here

Username:
Password:
Remember me
or

Create a New Account

You just need username and password

The following errors occured:
Username:
Email:
Password:
Verify password:
Remember me